Corcept Appoints Roberto Vieira as President, Oncology
January 29 2024 - 8:00AM
Corcept Therapeutics Incorporated (NASDAQ: CORT), a
commercial-stage company engaged in the discovery and development
of medications to treat severe endocrinologic, oncologic, metabolic
and neurologic disorders by modulating the effects of the hormone
cortisol, today announced the appointment of Roberto Vieira as
President, Oncology. He will report to Joseph K. Belanoff, MD,
Corcept’s Chief Executive Officer, and join the company’s Executive
Team.
Mr. Vieira joins Corcept from Mirati
Therapeutics, Inc., where he served as Senior Vice President of
U.S. Commercial until earlier this month. At Mirati, Mr. Vieira
built the U.S. commercial organization, inclusive of sales,
marketing and market access, and successfully led the launch of the
company’s first targeted cancer therapy for the treatment of
advanced non-small cell lung cancer. Mr. Vieira previously spent 15
years at Bristol-Myers Squibb in positions of increasing seniority,
including Vice President of Worldwide Oncology Strategy. Prior to
that, he also served as General Manager in Europe (The Netherlands)
and was part of the leadership team that led the introduction of
transformational medicines in the Immuno-Oncology space across a
broad range of solid tumors.
“We are thrilled to welcome Roberto to the
Corcept team,” said Dr. Belanoff. “His expertise in the global
commercialization of cancer medicines and in building
high-performing teams makes him an ideal leader for Corcept’s
oncology division.”
"I'm excited to lead Corcept's oncology
division, initially focusing on ovarian cancer and expanding to
other tumors. Together with our dedicated team, we aim to
revolutionize cancer treatment by leading the exciting field of
cortisol modulation. I'm committed to building a strong oncology
organization and launching first-in-class products that make a real
impact in patients' lives," said Mr. Vieira.
About Corcept’s Oncology
ProgramsThere is substantial evidence that cortisol
activity at the glucocorticoid receptor (“GR”) allows certain solid
tumors to resist treatment and that modulating cortisol’s activity
may help anti-cancer treatments achieve their intended effect.
Many types of solid tumors express the GR and
are potential targets for cortisol modulation therapy. In some
cancers, cortisol inhibits cellular apoptosis – the tumor-killing
effect many treatments are meant to stimulate. In other cancers,
cortisol activity promotes tumor growth. Cortisol also suppresses
the body’s immune response; activating – not suppressing – the
immune system is beneficial in fighting certain cancers.
Corcept is conducting clinical trials of its
proprietary selective cortisol modulators in combination with three
different anti-cancer treatments in patients with ovarian, adrenal
and prostate cancers.
About Corcept TherapeuticsFor
more than 25 years, Corcept’s focus on cortisol modulation and its
potential to treat patients across a wide variety of serious
disorders has led to the discovery of more than 1,000 proprietary
selective cortisol modulators. Corcept’s advanced clinical trials
are being conducted in patients with hypercortisolism, solid
tumors, amyotrophic lateral sclerosis (ALS) and liver disease
(NASH). In February 2012, the company introduced Korlym®, the first
medication approved by the U.S. Food and Drug Administration for
the treatment of patients with Cushing’s syndrome. Corcept is
headquartered in Menlo Park, California. For more information,
visit Corcept.com.
Forward-Looking
StatementsStatements in this press release, other than
statements of historical fact, are forward-looking statements based
on our current plans and expectations that are subject to risks and
uncertainties that might cause our actual results to differ
materially from those such statements express or imply. These risks
and uncertainties include, but are not limited to, our ability to
operate our business; risks related to the development of
relacorilant and our other product candidates, including their
clinical attributes, regulatory approvals, mandates, oversight and
other requirements; and the scope and protective power of our
intellectual property. These and other risks are set forth in our
SEC filings, which are available at our website and the SEC’s
website. We disclaim any intention or duty to update
forward-looking statements made in this press release.
CONTACTInvestor
inquiries:ir@corcept.comMedia inquiries:Communications@corcept.com
www.corcept.com
Corcept Therapeutics (NASDAQ:CORT)
Historical Stock Chart
From Apr 2024 to May 2024
Corcept Therapeutics (NASDAQ:CORT)
Historical Stock Chart
From May 2023 to May 2024